New Industry Advocacy Group for Biosimilars Launches


From DCAT Value Chain Insights (VCI)

By Regulatory News posted 05-18-2015 16:26

  

A coalition of 11 companies involved in the development and manufacturing of biopharmaceuticals and “biosimilar” medicines have formed the Biosimilars Forum as a nonprofit organization solely dedicated to expanding patient access to biosimilars in the United States. The founding members of the Biosimilars Forum represent companies with US biosimilars development portfolios, including: Actavis, Amgen, Boehringer Ingelheim, Coherus BioSciences, EMD Serono, Hospira, Merck, Pfizer, Samsung, Sandoz, and Teva. Many of these same companies provide branded biologic products, which provides expertise and experience in the science, development, manufacturing, regulation, and clinical applications of biological medicines. The Forum seeks to provide evidence-based information to educate and advocate for public policies and practices that encourage access, awareness, and adoption of biosimilars.

The recently elected officers of the Biosimilars Forum are President (Juliana Reed, vice president, global government affairs, Hospira, Inc.); Vice President (Hillel Cohen, Ph.D., executive director, scientific affairs, Sandoz Biopharmaceuticals (a Novartis company)); Treasurer (Geoffrey Eich, executive director, External affairs, Amgen Biosimilars); and Secretary (Stacie Phan, director, state government affairs and public policy, Boehringer Ingelheim).

Following its formation, Biosimilars Forum issued a public statement about the need for appropriate coding for biosimilars at the Centers for Medicare and Medicaid Services (CMS) Healthcare Common Procedure Coding System (HCPCS) Public Meeting on May 7, 2015.

Michael Werner, policy advisor with the Biosimilars Forum, issued a statement to say: "The Biosimilars Forum strongly believes that a scenario for payment that blends biosimilars into the same payment group/ASP [Average Sales Price] would be very detrimental to the adoption of biosimilars. Such a decision would not foster a sustainable or vibrant biosimilar market." Full details of its position may be found here.

Source: Biosimilars Forum

0 comments
76 views


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription 

Permalink